Elacestrant Emerging Drug Insight

“Elacestrant Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Elacestrant for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the Elacestrant for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the Elacestrant for ER+ve HER2-ve Breast Cancer. The Elacestrant market report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Elacestrant market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.

Elacestrant Drug Summary

Radius Pharmaceutical’s elacestrant is a selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once-daily oral treatment for HR+ breast cancer. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies to treat breast cancer.

In 2018, the company initiated and opened for enrollment a Phase III study (EMERALD) evaluating elacestrant as second- or third-line monotherapy in postmenopausal women with advanced/metastatic estrogen receptor positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. The study achieved its enrollment target of 466 patients who have received prior treatment with one or two lines of endocrine therapy, including a cyclin-dependent kinase (CDK) 4/6 inhibitor. In October 2021, the Radius and Menarini group jointly announced positive topline results from the EMERALD trial.

The results from the EMERALD clinical trial established that elacestrant is an effective treatment for metastatic hormone receptor-positive, HER2-negative breast cancer that stops responding to CDK 4/6 inhibitors. Based on this finding, the FDA granted priority review to elacestrant in August 2022.

Scope of the Elacestrant Market Report

The report provides insights into:

• A comprehensive product overview including the Elacestrant description, mechanism of action, dosage and administration, research and development activities in ER+ve HER2-ve Breast Cancer.
• Elaborated details on Elacestrant regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Elacestrant research and development activity in ER+ve HER2-ve Breast Cancer in detail across the United States.
• The report also covers the patents information with expiry timeline around Elacestrant.
• The report contains forecasted Elacestrant sales for ER+ve HER2-ve Breast Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ER+ve HER2-ve Breast Cancer.
• The Elacestrant market report also features the SWOT analysis with analyst views for Elacestrant in ER+ve HER2-ve Breast Cancer.

Methodology

The Elacestrant sales forecasting report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Elacestrant Analytical Perspective by DelveInsight

• In-depth Elacestrant Market Assessment

This Elacestrant market report provides a detailed market assessment of Elacestrant in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted Elacestrant sales data from 2023 to 2032.

• Elacestrant Clinical Assessment

The report provides the Elacestrant clinical trials information in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Elacestrant Market Report Highlights 

• In the coming years, the market scenario for ER+ve HER2-ve Breast Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Elacestrant dominance.
• Other emerging products for ER+ve HER2-ve Breast Cancer are expected to give tough market competition to Elacestrant and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Elacestrant in ER+ve HER2-ve Breast Cancer.
• Our in-depth analysis of the forecasted Elacestrant sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Elacestrant in ER+ve HER2-ve Breast Cancer.  

Key Questions

• What is the product type, route of administration and mechanism of action of Elacestrant?
• What is the Elacestrant clinical trial status of the study related to Elacestrant in ER+ve HER2-ve Breast Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Elacestrant development?
• What are the key designations that have been granted to Elacestrant for ER+ve HER2-ve Breast Cancer?
• What is the forecasted market scenario of Elacestrant for ER+ve HER2-ve Breast Cancer?
• What are the forecasted Elacestrant sales of Elacestrant in the United States? 
• What are the other emerging products available in ER+ve HER2-ve Breast Cancer and how are they giving competition to Elacestrant for ER+ve HER2-ve Breast Cancer?
• Which are the late-stage emerging therapies under development for the treatment of ER+ve HER2-ve Breast Cancer?